PRESIDENT, CEO AND CHAIRMAN, TARVEDA THERAPEUTICS
Watertown, Massachusetts, United States
Drew Fromkin has nearly 30 years of leadership experience in major areas of the healthcare industry.Prior becoming the CEO of Tarveda Therapeutics, Mr. Fromkin served as President, CEO and Director of Clinical Data, Inc. (NASDAQ: CLDA) where he transformed the Company from a traditional diagnostics business with a sub-$100 million market capitalization to an innovative biopharmaceutical and personalized medicine company. Clinical Data was acquired for $1.2 billion by Forest Laboratories. Prior to Clinical Data, Mr. Fromkin served as President and CEO of DoctorQuality, Inc. (acquired by Quantros, Inc.), President, CEO and Director of Endo Surgical Devices, Inc. and Corporate Vice President, Business Development, for Merck-Medco, a wholly-owned subsidiary of Merck & Co. Mr. Fromkin was named to Business Week's "CEOs 40 and Under" list while at Clinical Data. Mr. Fromkin holds a B.A. from Brandeis University.